Ezrin、CD44在胃癌组织中的表达及其相关性  

Expression and Correlation of Ezrin and CD44 in Gastric Carcinoma

作　　者：李莹杰[1] 陶晓峰[2] 贺岩[2] 付红[1] 

机构地区：[1]哈尔滨医科大学附属第二医院病理科,150086 [2]哈尔滨医科大学病理教研室

出　　处：《肿瘤防治研究》2008年第3期188-190,共3页Cancer Research on Prevention and Treatment

基　　金：黑龙江省卫生厅基金资助项目(2006-088);黑龙江省哈医大二院青年基金资助项目(2006-08)

摘　　要：目的探讨Ezrin、CD44在胃癌组织中的表达情况及其与临床病理参数之间的关系。方法采用免疫组化法检测50例胃癌组织、25例胃粘膜不典型增生和25例正常胃粘膜中Ezrin、CD44的表达并加以分析。结果①Ezrin在正常胃粘膜、不典型增生和胃癌中的阳性表达率分别为28.0%、36.0%和86.0%。CD44在正常胃粘膜、不典型增生和胃癌中的阳性表达率分别为0、16.0%和60.0%。Ezrin、CD44在正常胃粘膜、不典型增生和胃癌中的表达率逐渐上升,差异有统计学意义(P<0.01)。②Ezrin、CD44的表达程度均与胃癌的临床分期、淋巴结转移有关(P<0.05),与胃癌的分化程度无关(P>0.05)。③Ezrin和CD44的表达之间呈正相关(P<0.01)。结论Ezrin、CD44在胃癌中的高表达与胃癌的临床分期和淋巴结转移有关,二者的联合检测可能成为预测胃癌转移及预后的重要指标。Objective To investigate the expression of Ezrin and CD44 and their correlations with clinicalpathological parameters in gastric carcinoma. Methods The expression of Ezrin and CD44 in 50 specimens of gastric carcinoma, 25 specimens of gastric epithelial dysplasia and 25 specimens of normal gastric tissues were detected by immunohistochemistry method. Results 1.in normal gastric tissues, gastric dysplasia and gastric carcinoma, the percentage of Ezrin positive expression was 28. 0%, 36. 0% and 86. 0%, respectively, the percentage of CD44 expression was 0, 16. 0%and 60. 0%. The expression of Ezrin and CD44 increased gradually in normal gastric tissues, gastric dysplasia and gastric carcinoma. The difference has a statiftical significance（P〈0. 05）. 2.The expression of both Ezrin and CD44 was correlated to clinical stage, metastasis of lymph node, and there were substantial differences （P〈0. 01 ）, but theses were not correlated to carcinoma differentiation（P〉0. 05）. 3. The expression of Ezrin was positively correlated to that of CD44 in gastric carcinoma （P〈0. 01 ）. Conclusion The expression of Ezrin and CD44 was correlated to clinical stage and metastasis of lymph node. Joint examination of these two parameters is useful for forecast metastasis and prognosis of gastric carcinoma.

关 键 词：胃癌 EZRIN CD44 免疫组化 

分 类 号：R735.2[医药卫生—肿瘤]